Rubius Therapeutics

$6.42
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.50 (+8.45%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell RUBY and other stocks, options, and ETFs commission-free!

About RUBY

Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan on April 26, 2013 and is headquartered in Cambridge, MA. The listed name for RUBY is Rubius Therapeutics, Inc. Common Stock.

CEO
Pablo J. Cagnoni
Employees
223
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
519.53M
Price-Earnings Ratio
Dividend Yield
Average Volume
209.24K
High Today
$6.63
Low Today
$5.99
Open Price
$5.99
Volume
340.04K
52 Week High
$14.44
52 Week Low
$3.35

Collections

RUBY Earnings

-$0.60
-$0.40
-$0.20
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 11, Pre-Market

You May Also Like